Rapport Therapeutics, Inc.
RAPP
$11.44
$0.0550.48%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -13.93% | 3.22% | 20.06% | -67.68% | -55.23% |
| Total Depreciation and Amortization | 18.72% | 5.29% | 36.84% | 186.79% | 130.43% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 185.00% | -18.05% | -79.10% | 591.76% | 19.12% |
| Change in Net Operating Assets | 381.13% | -287.80% | 96.10% | -262.40% | -14.89% |
| Cash from Operations | 12.00% | -0.39% | 7.17% | -70.08% | -90.95% |
| Capital Expenditure | -61.43% | 85.52% | 9.79% | 25.40% | -2,663.46% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 160.79% | 50.16% | -159.80% | 47.10% | -- |
| Cash from Investing | 160.20% | 50.48% | -155.46% | 46.70% | -151,171.15% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 200.00% | -111.19% | -331.03% |
| Cash from Financing | 100.50% | -100.87% | 150.32% | 45,570.71% | -100.16% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 124.69% | -297.37% | 771.71% | 104.62% | -211.61% |